• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RCMNet:一种用于白血病的 CAR-T 疗法的深度学习模型。

RCMNet: A deep learning model assists CAR-T therapy for leukemia.

机构信息

Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, Guangdong 518055, China; Precision Medicine and Public Health, Tsinghua-Berkeley Shenzhen Institute, Tsinghua University, Shenzhen, Guangdong 518055, China.

The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China.

出版信息

Comput Biol Med. 2022 Nov;150:106084. doi: 10.1016/j.compbiomed.2022.106084. Epub 2022 Sep 11.

DOI:10.1016/j.compbiomed.2022.106084
PMID:36155267
Abstract

Acute leukemia is a type of blood cancer with a high mortality rate. Current therapeutic methods include bone marrow transplantation, supportive therapy, and chemotherapy. Although a satisfactory remission of the disease can be achieved, the risk of recurrence is still high. Therefore, novel treatments are demanding. Chimeric antigen receptor-T (CAR-T) therapy has emerged as a promising approach to treating and curing acute leukemia. To harness the therapeutic potential of CAR-T cell therapy for blood diseases, reliable cell morphological identification is crucial. Nevertheless, the identification of CAR-T cells is a big challenge posed by their phenotypic similarity with other blood cells. To address this substantial clinical challenge, herein we first construct a CAR-T dataset with 500 original microscopy images after staining. Following that, we create a novel integrated model called RCMNet (ResNet18 with Convolutional Block Attention Module and Multi-Head Self-Attention) that combines the convolutional neural network (CNN) and Transformer. The model shows 99.63% top-1 accuracy on the public dataset. Compared with previous reports, our model obtains satisfactory results for image classification. Although testing on the CAR-T cell dataset, a decent performance is observed, which is attributed to the limited size of the dataset. Transfer learning is adapted for RCMNet and a maximum of 83.36% accuracy is achieved, which is higher than that of other state-of-the-art models. This study evaluates the effectiveness of RCMNet on a big public dataset and translates it to a clinical dataset for diagnostic applications.

摘要

急性白血病是一种死亡率较高的血癌。目前的治疗方法包括骨髓移植、支持治疗和化疗。虽然可以达到满意的疾病缓解,但复发的风险仍然很高。因此,需要新的治疗方法。嵌合抗原受体 T 细胞(CAR-T)疗法已成为治疗和治愈急性白血病的一种有前途的方法。为了利用 CAR-T 细胞疗法治疗血液疾病的治疗潜力,可靠的细胞形态学识别是至关重要的。然而,CAR-T 细胞的鉴定是一个巨大的挑战,因为它们与其他血细胞具有相似的表型。为了解决这一重大的临床挑战,我们首先构建了一个包含 500 张原始显微镜图像的 CAR-T 数据集,这些图像经过染色。在此基础上,我们创建了一个名为 RCMNet(带有卷积块注意力模块和多头自注意力的 ResNet18)的新型集成模型,该模型结合了卷积神经网络(CNN)和 Transformer。该模型在公共数据集上的 top-1 准确率达到 99.63%。与之前的报告相比,我们的模型在图像分类方面取得了令人满意的结果。虽然在 CAR-T 细胞数据集上进行了测试,但观察到了不错的性能,这归因于数据集的规模有限。我们对 RCMNet 进行了迁移学习,最高可达到 83.36%的准确率,高于其他最先进的模型。本研究评估了 RCMNet 在大型公共数据集上的有效性,并将其转化为临床数据集用于诊断应用。

相似文献

1
RCMNet: A deep learning model assists CAR-T therapy for leukemia.RCMNet:一种用于白血病的 CAR-T 疗法的深度学习模型。
Comput Biol Med. 2022 Nov;150:106084. doi: 10.1016/j.compbiomed.2022.106084. Epub 2022 Sep 11.
2
ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.shRNA 介导的 PD-1 沉默增强嵌合抗原受体 T 细胞对皮下前列腺和白血病异种移植物的疗效。
Biomed Pharmacother. 2021 May;137:111339. doi: 10.1016/j.biopha.2021.111339. Epub 2021 Feb 4.
3
Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.在复发/难治性急性淋巴细胞白血病患者中,人源化 CD19 靶向嵌合抗原受体 T(CAR-T)细胞具有强大的抗白血病活性。
Am J Hematol. 2018 Jul;93(7):851-858. doi: 10.1002/ajh.25108. Epub 2018 Apr 28.
4
Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞治疗 B 细胞急性淋巴细胞白血病。
Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018.
5
Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia.寻找新途径:嵌合抗原受体(CAR)T 细胞治疗髓系白血病。
Cancer Rep (Hoboken). 2020 Apr;3(2):e1222. doi: 10.1002/cnr2.1222. Epub 2020 Jan 8.
6
CD19 CAR T cell product and disease attributes predict leukemia remission durability.CD19 CAR T 细胞产品和疾病特征可预测白血病缓解的持久度。
J Clin Invest. 2019 Mar 12;129(5):2123-2132. doi: 10.1172/JCI125423. Print 2019 May 1.
7
Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞疗法与移植的整合:CAR T 细胞或基于化疗的完全缓解后异基因造血干细胞移植在 B 细胞急性淋巴细胞白血病中的安全性和长期疗效比较。
Front Immunol. 2021 May 7;12:605766. doi: 10.3389/fimmu.2021.605766. eCollection 2021.
8
Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy.CAR T 细胞治疗后复发急性淋巴细胞白血病髓外疾病的假性进展。
Immunotherapy. 2021 Jan;13(1):5-10. doi: 10.2217/imt-2020-0188. Epub 2020 Oct 12.
9
An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.抗 CD19 嵌合抗原受体 T(CAR-T)细胞输注诱导缓解后复发性 B-ALL 患者治疗的分析性生物标志物。
Sci China Life Sci. 2016 Apr;59(4):379-85. doi: 10.1007/s11427-016-5035-4. Epub 2016 Mar 24.
10
Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.加速嵌合抗原受体疗法在慢性淋巴细胞白血病中的应用:嵌合抗原受体 T 细胞疗法治疗慢性淋巴细胞白血病的发展与挑战。
Am J Hematol. 2019 May;94(S1):S10-S17. doi: 10.1002/ajh.25457. Epub 2019 Mar 23.

引用本文的文献

1
Smart CAR-T Nanosymbionts: archetypes and proto-models.智能嵌合抗原受体T细胞纳米共生体:原型与原始模型
Front Immunol. 2025 Aug 12;16:1635159. doi: 10.3389/fimmu.2025.1635159. eCollection 2025.
2
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies.优化 CAR-T 细胞疗法治疗实体瘤:当前挑战与潜在策略。
J Hematol Oncol. 2024 Nov 5;17(1):105. doi: 10.1186/s13045-024-01625-7.
3
Advances in manufacturing chimeric antigen receptor immune cell therapies.嵌合抗原受体免疫细胞疗法的研究进展。
Semin Immunopathol. 2024 Aug 16;46(5):12. doi: 10.1007/s00281-024-01019-4.
4
Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy.超越 CAR-T:CAR-NK 细胞疗法在哮喘免疫治疗中的兴起。
J Transl Med. 2024 Aug 5;22(1):736. doi: 10.1186/s12967-024-05534-8.
5
CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.CAR-NKT 细胞在哮喘中的应用:NKT 作为 CAR 治疗有前途的细胞的应用。
Clin Rev Allergy Immunol. 2024 Jun;66(3):328-362. doi: 10.1007/s12016-024-08998-0. Epub 2024 Jul 12.
6
Detection of Frog Virus 3 by Integrating RPA-CRISPR/Cas12a-SPM with Deep Learning.通过将重组酶聚合酶扩增-成簇规律间隔短回文重复序列/Cas12a-表面等离子体激元共振与深度学习相结合检测蛙病毒3
ACS Omega. 2023 Aug 25;8(36):32555-32564. doi: 10.1021/acsomega.3c02929. eCollection 2023 Sep 12.
7
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.利用 CAR-T 细胞疗法的潜力:血液系统恶性肿瘤和实体瘤治疗的进展、挑战和未来方向。
J Transl Med. 2023 Jul 7;21(1):449. doi: 10.1186/s12967-023-04292-3.
8
Search, identification, and curation of cell and gene therapy product regulations using augmented intelligent systems.使用增强智能系统搜索、识别和整理细胞与基因治疗产品法规。
Front Med (Lausanne). 2023 Mar 6;10:1072767. doi: 10.3389/fmed.2023.1072767. eCollection 2023.